A retrospective, multicentre study analysing treatment patterns and outcomes in patients with Head and Neck Cancer
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Platinum complexes (Primary) ; Antineoplastics; Immunotherapies; Taxanes
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Pharyngeal neoplasms; Squamous cell cancer; Tongue cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 04 Aug 2021 New trial record
- 28 Jul 2021 Results published in the Advances in Therapy